Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
12/04/202421:05IH Market NewsParamount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202421:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202421:00Business WireFASENRA approved for treatment of children aged 6 to 11 with severe asthmaNASDAQ:AZNAstraZeneca PLC
06/04/202414:10Business WireENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid TumorsNASDAQ:AZNAstraZeneca PLC
06/04/202412:43Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumorsNASDAQ:AZNAstraZeneca PLC
05/04/202422:00Business WireIMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trialNASDAQ:AZNAstraZeneca PLC
02/04/202422:00Business WireDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
02/04/202417:00Business WireDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerNASDAQ:AZNAstraZeneca PLC
01/04/202422:00Business WireVOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNHNASDAQ:AZNAstraZeneca PLC
27/03/202421:54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNASDAQ:AZNAstraZeneca PLC
26/03/202422:20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNASDAQ:AZNAstraZeneca PLC
25/03/202422:00Business WireULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)NASDAQ:AZNAstraZeneca PLC
19/03/202422:33IH Market NewsUnilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and MoreNASDAQ:AZNAstraZeneca PLC
19/03/202422:00Business WireAstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancerNASDAQ:AZNAstraZeneca PLC
19/03/202421:52IH Market NewsAstraZeneca to acquire Fusion for $2 billionNASDAQ:AZNAstraZeneca PLC
18/03/202422:00Business WireAstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolioNASDAQ:AZNAstraZeneca PLC
14/03/202422:39IH Market NewsFisker’s Shares Take a Hit Amid Speculation of Bankruptcy, Altria Divests from AB InBev to Fund Stock Repurchase InitiativeNASDAQ:AZNAstraZeneca PLC
13/03/202422:06Business WireAstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPDNASDAQ:AZNAstraZeneca PLC
07/03/202421:43IH Market NewsTesla Exits Market Top 10, Victoria’s Secret Stock Tumbles 30% on Weak ForecastNASDAQ:AZNAstraZeneca PLC
27/02/202408:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
27/02/202401:00PR Newswire (Canada)Alexion Canada donne de la couleur aux maladies rares avec la campagne internationale colourUp4RARENASDAQ:AZNAstraZeneca PLC
27/02/202401:00PR Newswire (Canada)Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE CampaignNASDAQ:AZNAstraZeneca PLC
26/02/202422:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
24/02/202408:09Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:AZNAstraZeneca PLC
24/02/202405:23Business WireMANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRANASDAQ:AZNAstraZeneca PLC
23/02/202401:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
23/02/202401:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
19/02/202423:10Business WireDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
19/02/202423:05Business WireTAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trialNASDAQ:AZNAstraZeneca PLC
19/02/202418:00Business WireDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN